serologically active patients

Related by string. * : serologically active SLE . serologically active systemic lupus . serologically / actives . ACTIVE . Actives . www.active : Active Pharmaceutical Ingredients . active antiretroviral therapy . Active Older Adults . active shutter glasses / pa tients . PATIENTS . PATIENT . Patients : Breast Cancer Patients . terminally ill patients . Patient Safety . chronically ill patients * *

Related by context. Frequent words. (Click for all words.) 65 plus methotrexate 63 DAS# [002] 63 adalimumab 63 Secondary endpoints include 63 Secondary endpoints included 63 cytogenetic response 63 virologic response 62 belimumab 62 inflammatory lesions 62 IPSS 61 COPD exacerbations 61 ADAS cog 61 peginterferon alfa 2a 61 Disease Activity 61 laboratory abnormalities 61 HbA 1c 61 annualized relapse 61 sustained virologic response 60 certolizumab pegol 60 placebo p 59 HRQoL 59 febrile neutropenia 59 discontinuations due 59 placebo p = 59 PANSS 59 T2DM 59 CI -#.# 59 RLS symptoms 59 mg BID 59 tolvaptan 59 Secondary endpoints 59 patients evaluable 59 symptom severity 59 mg kg dose 58 decitabine 58 DMARD 58 achieved statistical significance 58 lymphopenia 58 P = .# 58 ACR# [002] 58 virologic failure 58 treatment emergent adverse 58 gout flares 58 COPAXONE R 58 PsA 58 Ischemic 58 etanercept 58 hypomagnesemia 58 ADHF 58 fasting insulin 58 TAXUS Stent 58 interferon alfa 58 mg QD 57 fasting plasma glucose 57 hypokalemia 57 hypercalcemia 57 serum uric acid 57 MetS 57 mycophenolate mofetil 57 cerebrovascular events 57 LUTS 57 thromboembolic events 57 bosentan 57 virologic 57 HbA1c levels 57 plus dexamethasone 57 HSCT 57 nonsignificant 57 cabazitaxel 57 peginterferon 57 cardiometabolic risk 57 teriparatide 57 albuminuria 57 secondary endpoint 57 hyperglycaemia 57 HRQOL 56 cardiac dysfunction 56 dasatinib 56 confidence interval #.#-#.# 56 tipranavir 56 Solid Tumors 56 tamsulosin 56 Pioglitazone 56 glycemia 56 serum sodium 56 log# 56 STELARA 56 glycated hemoglobin 56 vasomotor symptoms 56 fasting glucose levels 56 estimated glomerular filtration 56 dysmenorrhea 56 microalbuminuria 56 tocilizumab 56 antibody titers 55 secondary efficacy endpoints 55 thrombotic events 55 nonadherence 55 subscales 55 dyspnea 55 serum phosphorus

Back to home page